Profile data is unavailable for this security.
About the company
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing its technology to harness the power of the immune system to combat cancer. Its product candidate, CMP-001, is a differentiated Toll-like receptor 9 (TLR9), agonist delivered as a biologic virus-like particle (VLP), utilizing a CpG-A oligonucleotide as a key component. When injected into a tumor, CMP-001 is designed to trigger the body’s innate immune system, thereby altering the tumor microenvironment and directing activated anti-tumor T cells to attack both the injected tumor and also tumors throughout the body. The Company is also developing CMP-001 in combination with several checkpoint inhibitor immunotherapies in melanoma and head and neck cancer.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2015
- Employees22.00
- LocationCheckmate Pharmaceuticals Inc245 Main Street, 2Nd FloorCAMBRIDGE 02142United StatesUSA
- Phone+1 (978) 503-2124
- Fax+1 (302) 655-5049
- Websitehttp://checkmatepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cerecor Inc | 5.78m | -53.88m | 305.28m | 18.00 | -- | 6.80 | -- | 52.79 | -0.9193 | -0.7387 | 0.0986 | 0.5149 | 0.0994 | 1.29 | 1.75 | 321,290.60 | -92.58 | -39.12 | -130.53 | -59.31 | 95.40 | -- | -931.58 | -150.75 | 2.48 | -- | 0.00 | -- | -3.96 | -- | 55.94 | -- | 68.13 | -- |
| Vistagen Therapeutics Inc | 334.00k | -16.98m | 306.18m | 9.00 | -- | 38.77 | -- | 916.71 | -0.3437 | -0.3437 | 0.0064 | 0.0571 | 0.023 | -- | -- | 37,111.11 | -107.93 | -354.97 | -145.02 | -755.47 | -- | -- | -4,686.47 | -9,374.84 | -- | -1,757.49 | 0.0953 | -- | -- | -- | 14.35 | -- | -- | -- |
| CytomX Therapeutics Inc | 92.27m | -53.64m | 307.39m | 158.00 | -- | 6.40 | -- | 3.33 | -1.17 | -1.17 | 2.01 | 1.04 | 0.2468 | -- | 335.52 | 583,974.70 | -14.35 | -24.00 | -18.84 | -29.18 | -- | -- | -58.14 | -165.55 | -- | -- | 0.00 | -- | -3.38 | 62.48 | -20.84 | -- | 16.03 | -- |
| Galecto Inc | 0.00 | -56.73m | 309.95m | 23.00 | -- | -- | -- | -- | -2.29 | -2.29 | 0.00 | 3.53 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -29.09 | 0.00 | -- | -- | -- | -121.35 | -- | -- | -- |
| Matinas BioPharma Holdings Inc | 95.83k | -22.49m | 311.13m | 21.00 | -- | 4.83 | -- | 3,246.68 | -0.1207 | -0.1207 | 0.0005 | 0.3428 | 0.0016 | -- | -- | 4,563.33 | -36.25 | -85.60 | -37.98 | -97.81 | -- | -- | -22,622.13 | -11,499.32 | -- | -- | 0.0009 | -- | -25.00 | -- | -22.08 | -- | 7.05 | -- |
| Alpine Immune Sciences Inc | 4.58m | -27.74m | 312.30m | 53.00 | -- | 4.63 | -- | 68.25 | -1.44 | -1.44 | 0.2345 | 2.83 | 0.0418 | -- | 1.78 | 86,339.63 | -25.36 | -26.54 | -32.78 | -28.85 | -- | -- | -606.16 | -1,154.15 | -- | -101.75 | 0.1298 | -- | 146.81 | -- | -14.70 | -- | 188.61 | -- |
| NuCana PLC (ADR) | 0.00 | -35.75m | 314.13m | 31.00 | -- | 2.08 | -- | -- | -1.08 | -1.08 | 0.00 | 2.95 | 0.00 | -- | -- | 0.00 | -26.69 | -- | -28.83 | -- | -- | -- | -- | -- | -- | -25.30 | 0.0065 | -- | -- | -- | -54.71 | -- | -- | -- |
| Vyne Therapeutics Inc | 16.71m | -253.89m | 315.61m | 180.00 | -- | 6.37 | -- | 18.89 | -3.19 | -3.19 | 0.1791 | 0.295 | 0.1636 | -- | -- | 417,675.00 | -248.59 | -- | -295.88 | -- | 94.86 | -- | -1,519.63 | -- | 3.95 | -154.14 | 0.40 | -- | -100.00 | -- | -43.27 | -- | -- | -- |
| Natures Sunshine Products Inc | 375.16m | 16.47m | 317.48m | 834.00 | 19.39 | 2.15 | 11.17 | 0.8463 | 0.8328 | 0.8328 | 18.99 | 7.51 | 1.66 | 2.12 | 45.57 | 449,828.50 | 7.75 | 0.4246 | 10.86 | 0.6076 | 73.68 | 73.66 | 4.67 | 0.2445 | 1.48 | -- | 0.0302 | 216.57 | -0.7113 | -0.2277 | 892.15 | -19.47 | -27.95 | -- |
| Checkmate Pharmaceuticals Inc | -100.00bn | -100.00bn | 321.10m | 22.00 | -- | 2.37 | -- | -- | -- | -- | -- | 6.27 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -39.48 | -- | -- | -- |
| Verrica Pharmaceuticals Inc | 0.00 | -37.35m | 326.94m | 17.00 | -- | 8.34 | -- | -- | -1.50 | -1.50 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -47.89 | -- | -66.30 | -- | -- | -- | -- | -- | -- | -29.74 | 0.4717 | -- | -- | -- | -36.61 | -- | -- | -- |
| Concert Pharmaceuticals Inc | 7.91m | -72.86m | 331.01m | 70.00 | -- | 2.52 | -- | 41.86 | -2.57 | -2.57 | 0.2728 | 4.29 | 0.0518 | -- | 112.17 | 112,971.40 | -47.73 | -8.54 | -51.27 | -9.08 | -- | -- | -921.38 | -29.27 | -- | -83.44 | 0.00 | -- | -89.75 | -33.96 | -39.52 | -- | -3.15 | -- |
| Fortress Biotech Inc | 42.98m | -56.72m | 331.71m | 93.00 | -- | 3.42 | -- | 7.72 | -0.853 | -0.853 | 0.642 | 1.04 | 0.1661 | 13.92 | 4.13 | 462,150.50 | -44.62 | -54.56 | -75.68 | -104.82 | 67.72 | -- | -268.61 | -463.97 | 6.35 | -6.66 | 0.2464 | -- | 36.26 | -- | 45.27 | -- | -- | -- |
| Ampio Pharmaceuticals Inc | 0.00 | -12.30m | 333.10m | 23.00 | -- | 30.87 | -- | -- | -0.0745 | -0.0745 | 0.00 | 0.0583 | 0.00 | -- | -- | 0.00 | -78.07 | -55.21 | -90.41 | -63.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -140.10 | -- | -69.74 | -- |
| MEI Pharma Inc | 31.59m | -45.11m | 336.44m | 51.00 | -- | 4.09 | -- | 10.65 | -0.5196 | -0.5196 | 0.3256 | 0.7317 | 0.2233 | -- | 10.80 | 619,411.80 | -31.89 | -28.33 | -37.38 | -31.81 | 92.11 | -- | -142.81 | -206.30 | -- | -1.56 | 0.00 | -- | 488.26 | -- | -173.60 | -- | 126.49 | -- |
Data as of Jan 22 2021. Currency figures normalised to Checkmate Pharmaceuticals Inc's reporting currency: US Dollar USD
13.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Clough Capital Partners LPas of 09 Nov 2020 | 1.33m | 6.18% |
| Sectoral Asset Management, Inc.as of 30 Sep 2020 | 600.69k | 2.79% |
| DWS Investment GmbHas of 30 Sep 2020 | 250.00k | 1.16% |
| BlackRock Fund Advisorsas of 30 Sep 2020 | 211.79k | 0.98% |
| Ensign Peak Advisors, Inc.as of 30 Sep 2020 | 119.92k | 0.56% |
| Millennium Management LLCas of 30 Sep 2020 | 109.07k | 0.51% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2020 | 55.64k | 0.26% |
| The Vanguard Group, Inc.as of 30 Sep 2020 | 55.22k | 0.26% |
| CaaS Capital Management LPas of 30 Sep 2020 | 44.97k | 0.21% |
| SSgA Funds Management, Inc.as of 30 Sep 2020 | 39.05k | 0.18% |
More ▼
Data from 30 Sep 2020 - 30 Sep 2020Source: FactSet Research Systems Inc.
